{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:33:40Z","timestamp":1787160820910,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ejca.2016.11.028","type":"journal-article","created":{"date-parts":[[2017,1,2]],"date-time":"2017-01-02T18:46:34Z","timestamp":1483382794000},"page":"215-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Linking uterine serous carcinoma to BRCA1\/2-associated cancer syndrome: A meta-analysis and case report"],"prefix":"10.1016","volume":"72","author":[{"given":"M.M.","family":"de Jonge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Mooyaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.G.","family":"Vreeswijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.D.","family":"de Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van Wezel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"van Asperen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.T.H.B.M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.M.","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2016.11.028_bib1","article-title":"Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Plataniotis","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2016.11.028_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00000478-198203000-00002","article-title":"Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma","volume":"6","author":"Hendrickson","year":"1982","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.ejca.2016.11.028_bib3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2016.11.028_bib4","series-title":"Endometriumcarcinoom. Landelijke richtlijn met regionale toevoegingen","author":"Integraal Kankercentrum Nederland","year":"2011"},{"issue":"Suppl. 6","key":"10.1016\/j.ejca.2016.11.028_bib5","article-title":"Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Colombo","year":"2013","journal-title":"Ann Oncol"},{"issue":"7447","key":"10.1016\/j.ejca.2016.11.028_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.ejca.2016.11.028_bib7","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/jnci\/djs345","article-title":"Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses","volume":"104","author":"Kuhn","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ejca.2016.11.028_bib8","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ejca.2016.11.028_bib9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.0.CO;2-U","article-title":"The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways","volume":"88","author":"Lax","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2016.11.028_bib10","first-page":"228","article-title":"A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses","volume":"81","author":"Lax","year":"1997","journal-title":"Verh Dtsch Ges Pathol"},{"issue":"11","key":"10.1016\/j.ejca.2016.11.028_bib11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2016.11.028_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.ejca.2016.11.028_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2015.12.034","article-title":"Germline mutations of the DNA repair pathways in uterine serous carcinoma","volume":"141","author":"Frimer","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2016.11.028_bib14","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","article-title":"Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer\u2013results from two randomised studies","volume":"46","author":"Hogberg","year":"2010","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2016.11.028_bib15","first-page":"1531","article-title":"BRCA germline mutations in women with uterine serous carcinoma\u2013still a debate","volume":"20","author":"Lavie","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2016.11.028_bib16","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2016.11.028_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/gyno.2000.6003","article-title":"Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?","volume":"79","author":"Goshen","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2016.11.028_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jnci\/djh008","article-title":"BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer","volume":"96","author":"Niell","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejca.2016.11.028_bib19","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/302320","article-title":"The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews","volume":"64","author":"Hartge","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.ejca.2016.11.028_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.ejca.2016.11.028_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ygyno.2010.08.027","article-title":"The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients","volume":"119","author":"Barak","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2016.11.028_bib22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/IGC.0b013e3181ef622d","article-title":"BRCA1\/2 germline mutations in Jewish patients with uterine serous carcinoma","volume":"20","author":"Bruchim","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2016.11.028_bib23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.yexmp.2012.06.004","article-title":"Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis","volume":"94","author":"van Eijk","year":"2013","journal-title":"Exp Mol Pathol"},{"issue":"18","key":"10.1016\/j.ejca.2016.11.028_bib24","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1158\/1078-0432.CCR-14-0571","article-title":"Functional ex\u00a0vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment","volume":"20","author":"Naipal","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2016.11.028_bib25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/gyno.2000.6082","article-title":"Risk of endometrial carcinoma associated with BRCA mutation","volume":"80","author":"Levine","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2016.11.028_bib26","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6604305","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions","volume":"98","author":"Antoniou","year":"2008","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2016.11.028_bib27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/91.11.943","article-title":"Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer","volume":"91","author":"Peto","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.ejca.2016.11.028_bib28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1054\/bjoc.2000.1407","article-title":"Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group","volume":"83","author":"Group ABCS","year":"2000","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2016.11.028_bib29","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/modpathol.2012.169","article-title":"Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers","volume":"26","author":"Reitsma","year":"2013","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.ejca.2016.11.028_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2006.08.004","article-title":"The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study","volume":"104","author":"Beiner","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2016.11.028_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2559.2004.01787.x","article-title":"WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma","volume":"44","author":"Al-Hussaini","year":"2004","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.ejca.2016.11.028_bib32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1309\/K84K-005F-TCB8-FV4B","article-title":"WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas","volume":"117","author":"Goldstein","year":"2002","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.ejca.2016.11.028_bib33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cncr.27720","article-title":"BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma","volume":"119","author":"Pennington","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2016.11.028_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jmoldx.2014.11.004","article-title":"Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and\/or ovarian cancer","volume":"17","author":"Trujillano","year":"2015","journal-title":"J Mol Diagn"},{"issue":"5","key":"10.1016\/j.ejca.2016.11.028_bib35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/humu.21438","article-title":"LOVD v.2.0: the next generation in gene variant databases","volume":"32","author":"Fokkema","year":"2011","journal-title":"Hum Mutat"},{"issue":"Suppl. 6","key":"10.1016\/j.ejca.2016.11.028_bib36","article-title":"Founder mutations in BRCA1 and BRCA2 genes","volume":"18","author":"Ferla","year":"2007","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2016.11.028_bib37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1006\/gyno.1999.5568","article-title":"Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature","volume":"75","author":"Hornreich","year":"1999","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2016.11.028_bib38","first-page":"28","article-title":"BRCA1 germline mutations in women with uterine serous papillary carcinoma","volume":"96","author":"Lavie","year":"2000","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ejca.2016.11.028_bib39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ygyno.2004.03.048","article-title":"Endometrial pathologies associated with postmenopausal tamoxifen treatment","volume":"94","author":"Cohen","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2016.11.028_bib40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2013.03.027","article-title":"The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study","volume":"130","author":"Segev","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2016.11.028_bib41","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1186\/bcr3206","article-title":"Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries","volume":"14","author":"Jones","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"15","key":"10.1016\/j.ejca.2016.11.028_bib42","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2016.11.028_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2016.11.028_bib44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2014.02.039","article-title":"PARP inhibitors in ovarian cancer: current status and future promise","volume":"133","author":"Liu","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2016.11.028_bib45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/IGC.0000000000000609","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"26","author":"Colombo","year":"2016","journal-title":"Int J Gynecol Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916330659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916330659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T23:28:48Z","timestamp":1568676528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916330659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":45,"alternative-id":["S0959804916330659"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.11.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linking uterine serous carcinoma to BRCA1\/2-associated cancer syndrome: A meta-analysis and case report","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}